10 recruiting, 5 completed, 3 not yet recruiting, 1 terminated. 8 Phase 2, 4 Not applicable, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 5, Completed 2, Not yet recruiting 1 |
| Not applicable | 4 | Recruiting 3, Not yet recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Prostate Cancer Metastatic Disease: new trials by email Literature Review of Prostate Cancer Metastatic Disease trials Research Report on Prostate Cancer Metastatic Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of OTL78 0.06 mg/kg ZOPOCIANINE given 1-7 days prior to surgery - Prostate Cancer Surgery, Prostate Cancer Metastatic Disease | Phase 2 / Phase 3 | Recruiting | Clinton Bahler | 45 | 2026-12-01 | 2026-10-22 |
| Patients With Metastasized Prostate Cancer Whose Prostate-specific Antigen-level (PSA) Remains >0,2 ng/ml After Six Months of Dual Antihormonal Therapy Will Receive Radiotherapy to the Prostate and Radiotherapy to Refractory Metastases Radiotherapy to the prostate and to PSMA-PET positive metastases - Prostate Cancer, Prostate Cancer Metastatic Disease | Not applicable | Not yet recruiting | University Hospital Tuebingen | 27 | 2026-07-01 | 2026-06-12 |
| HIghly MetAstatic Life Prolonging Therapy-Resistant Prostate Cancer: Role of Stereotactic Radiotherapy for Bone and Lymph Node Metastases (HIMARS) Stereotactic body radiotherapy (SBRT) - Prostate Cancer Metastatic Disease, Oligometastatic Prostate Cancer (OMPC) | Not applicable | Recruiting | Institut Cancerologie de l'Ouest | 18 | 2026-06-01 | 2026-06-04 |
| Lab Research Using Mini-tumors to Study Prostate Cancer Treatments HDR brachytherapy, Diagnostic biopsy - Prostate Cancer, Prostate Cancer Metastatic Disease | Recruiting | Maastricht Radiation Oncology | 600 | 2026-03-15 | 2026-04-23 | |
| Using FAPI PET/MRI to Evaluate Prostate Cancer FAPI, Positron Emission Tomography (PET), Magnetic Resonance Imaging - Prostate Cancer Metastatic Disease, Prostate Cancers | Phase 2 | Recruiting | University of Wisconsin, Madison | 30 | 2026-02-27 | 2026-06-10 |
| Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma) | Phase 2 | Recruiting | Shehzad Basaria, M.D. | 60 | 2026-01-14 | 2026-08-17 |
| PSMA PET for Surveillance After Focal Therapy PSMA PET/CT scan - Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis) | Not applicable | Recruiting | University of Chicago | 62 | 2025-11-19 | 2026-02-17 |
| Efficacy and Tolerability of Low-Dose Enzalutamide in Prostate Cancer Prostate Cancer Metastatic Disease | Not yet recruiting | Monica Boitano | 150 | 2025-09-01 | 2025-07-16 | |
| Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease | Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 192 | 2025-08-01 | 2026-03-25 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer [68Ga]Ga-OncoACP3 - Prostate Cancer, Prostate Cancer Metastatic Disease | Phase 1 | Completed | Philogen S.p.A. | 20 | 2025-04-08 | 2026-01-06 |
| Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection 0.03mg/kg ZOPOCIANINE given day of surgery, 0.06mg/kg ZOPOCIANINE given day of surgery, 0.03mg/kg ZOPOCIANINE given day prior to surgery - Prostate Cancer Surgery, Prostate Cancer Metastatic Disease | Phase 2 | Completed | Clinton Bahler | 22 | 2025-04-02 | 2026-08-13 |
| Study of HRS-2189 Combined HRS-5041 in Prostate Cancer HRS-2189, HRS-5041 - Prostate Cancer Metastatic Disease | Phase 2 | Not yet recruiting | Fudan University | 90 | 2024-12-31 | 2024-12-18 |
| Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC Intense androgen deprivation therapy, Radiation Therapy, radical prostatectomy - Prostate Cancer Metastatic Disease | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 144 | 2024-08-01 | 2025-05-28 |
| The Prognostic Value of PET/CT for Tumor Progression in Patients With Metastatic Hormone-sensitive Prostate Cancer Prostate Cancer Metastatic Disease, PET / CT | Completed | Sun Yat-sen University | 45 | 2024-06-02 | 2025-04-08 | |
| Role of Race in Nutritional Approach in Men on ADT Hypocaloric anti-inflammatory diet - Prostate Cancer Metastatic Disease | Not applicable | Recruiting | University of California, Los Angeles | 70 | 2024-03-28 | 2025-12-15 |
| Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate Cancer Prostate Cancer Metastatic Disease | Recruiting | University Hospital, Grenoble | 130 | 2023-08-01 | 2025-12-26 | |
| o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer Tadalafil 5 mg - Prostate Cancer Metastatic Disease, Chemotherapy Induced Peripheral Neuropathy (CIPN) | Phase 2 | Completed | Tri-Service General Hospital (TSGH) | 90 | 2020-01-05 | 2026-01-12 |
| Osteosclerotic Changes on CT Predict Survival in Prostate Cancer Osteosclerotic Changes on Computed Tomography - Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease | Completed | Sun Yat-sen University | 211 | 2010-07-01 | 2025-03-21 | |
| Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer Docetaxel, Biosyn, Prednisone - Urologic Neoplasms, Prostate Cancer | Phase 1 | Terminated | Sandy Srinivas | 2 | 2010-04-01 | 2017-03-15 |
Prostatic Neoplasms (10) · Adenocarcinoma (3) · Disease (1) · Hot Flashes (1) · Multiple Endocrine Neoplasia Type 1 (1) · Neoplasm Metastasis (1) · Neurotoxicity Syndromes (1) · Peripheral Nervous System Diseases (1) · Urologic Neoplasms (1)
Genital Diseases (10) · Genital Diseases, Male (10) · Genital Neoplasms, Male (10) · Male Urogenital Diseases (10) · Neoplasms (10) · Neoplasms by Site (10) · Prostatic Diseases (10) · Urogenital Diseases (10) · Urogenital Neoplasms (10) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Pathological Conditions, Signs and Symptoms (3) · Pathologic Processes (2) · Chemically-Induced Disorders (1)
Androgen Antagonists (1) · Docetaxel (1) · Gonadotropin-Releasing Hormone (1) · Magnetic Resonance Spectroscopy (1) · Prednisone (1) · Radiosurgery (1) · Radiotherapy (1) · Tadalafil (1) · abiraterone (1) · apalutamide (1)
Clinton Bahler (2) · Sun Yat-sen University (2) · Fudan University (1) · Institut Cancerologie de l'Ouest (1) · Maastricht Radiation Oncology (1) · Monica Boitano (1) · Philogen S.p.A. (1) · Sandy Srinivas (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shehzad Basaria, M.D. (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Tri-Service General Hospital (TSGH) (1) · University Hospital Tuebingen (1) · University Hospital, Grenoble (1) · University of California, Los Angeles (1)
United States (7) · China (4) · France (2) · Italy (2) · Netherlands (1) · Taiwan (1)
Clint Bahler, MD (2) · Abhinav Sidana, MD (1) · Ali Pirasteh, MD (1) · Andrea De Censi (1) · Dingwei Ye, Chief physician (1) · Dr. Sandy Srinivas (1) · Elgin Hoffmann, MD (1) · Evert J Van Limbergen, PhD, MD (1) · Fangzheng Xiang (1) · Hongqian Guo, PhD (1) · Matthew Rettig, MD (1) · Shehzad S Basaria, MD (1) · Zhaoping Li, MD, PhD (1)
PMID 34161051, PMID 35422442, PMID 36008120, PMID 36215568, PMID 37432081, PMID 37550494, PMID 37770114